# A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct03131687` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03131687](<https://clinicaltrials.gov/study/NCT03131687>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03131687

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 318 participants.

## Technical summary

Registry record NCT03131687. Randomized; double masking; primary purpose treatment. Start 2017-05-24 (actual); primary completion 2018-08-01 (actual). Results posted on 2019-08-20.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 318 participants (enrolled count; ClinicalTrials.gov record NCT03131687, source copy `cardio:ctgov-nct03131687-2019-08-20`, retrieved 2026-10-26)
- Started: 2017-05-24 (actual) (ClinicalTrials.gov record NCT03131687, source copy `cardio:ctgov-nct03131687-2019-08-20`, retrieved 2026-10-26)
- Primary completion: 2018-08-01 (actual) (ClinicalTrials.gov record NCT03131687, source copy `cardio:ctgov-nct03131687-2019-08-20`, retrieved 2026-10-26)
- Completion: 2018-08-01 (actual) (ClinicalTrials.gov record NCT03131687, source copy `cardio:ctgov-nct03131687-2019-08-20`, retrieved 2026-10-26)
- Results first posted: 2019-08-20 (ClinicalTrials.gov record NCT03131687, source copy `cardio:ctgov-nct03131687-2019-08-20`, retrieved 2026-10-26)
- Countries: United States; Poland; Puerto Rico; Slovakia (ClinicalTrials.gov record NCT03131687, source copy `cardio:ctgov-nct03131687-2019-08-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03131687-2019-08-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): tirzepatide
- Intervention (Drug): Dulaglutide
- Intervention (Drug): Placebo
- Lead sponsor: Eli Lilly and Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Tirzepatide (`cardio:tirzepatide`)
- Registry lists this organization as the lead sponsor: Eli Lilly and Company (`cardio:eli-lilly`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial (`cardio:pubmed-30293770`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes (`cardio:pubmed-32291277`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes (`cardio:pubmed-34608929`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 1e2a21c1e56829a58735f53f7a0539655a428fcf9d1f5f8404dc773ac191046c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
